RESUMO
Overexpression of the gene encoding the beta-amyloid precursor protein (APP) may have a key role in the pathogenesis of both Alzheimer's disease (AD) and Down Syndrome (DS). We have therefore introduced a 650 kilobase (kb) yeast artificial chromosome (YAC) that contains the entire, unrearranged 400 kb human APP gene into mouse embryonic stem (ES) cells by lipid-mediated transfection. ES lines were generated that contain a stably integrated, unrearranged human APP gene. Moreover, we demonstrate germ line transmission of the APP YAC in transgenic mice and expression of human APP mRNA and protein at levels comparable to endogenous APP. This transgenic strategy may prove invaluable for the development of mouse models for AD and DS.
Assuntos
Precursor de Proteína beta-Amiloide/genética , Proteínas Recombinantes de Fusão/biossíntese , Precursor de Proteína beta-Amiloide/biossíntese , Animais , Sequência de Bases , Cromossomos Artificiais de Levedura , Regulação da Expressão Gênica , Genes , Genoma Humano , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Dados de Sequência Molecular , Especificidade de Órgãos , Reação em Cadeia da Polimerase , Células-TroncoRESUMO
Advances in yeast artificial chromosome (YAC) technologies over the past decade have enabled the precise identification and manipulation of large genomic regions (>100 kb) of DNA. Introduction of YACs into the mouse germline has now been accomplished through transfection of mouse embryonic stem cells as well as through pronuclear microinjection, allowing the efficient transfer defined genomic loci into mice. YAC transgenics will have a profound impact on the development of transgenic mice as bioreactors and as models of human disease, and on the functional analysis of higher order genomic structure.
Assuntos
Cromossomos Artificiais de Levedura/genética , Doenças Genéticas Inatas/genética , Camundongos Transgênicos/genética , Animais , Modelos Animais de Doenças , Expressão Gênica , Humanos , Mamíferos/genética , Camundongos , Modelos Genéticos , Esferoplastos/genéticaRESUMO
Recent advances in the understanding of the genetic basis of Alzheimer's disease have enabled the production of transgenic mouse models of the disease. Utilizing both cDNA- and genomic-based approaches, these mouse models for Alzheimer's disease have already provided valuable insights into the pathogenesis of the disease and potential therapeutic interventions.
Assuntos
Doença de Alzheimer/genética , Doença de Alzheimer/etiologia , Doença de Alzheimer/terapia , Precursor de Proteína beta-Amiloide/genética , Animais , DNA Complementar/genética , Modelos Animais de Doenças , Genômica , Humanos , Camundongos , Camundongos Transgênicos , MutaçãoRESUMO
The retinoic acid-induced differentiation of F9 cells into parietal endoderm-like cells activates transcription of the endogenous mouse retrovirus, the intracisternal A-particle (IAP). To investigate the elements that control IAP gene differentiation-specific expression, we used methylation interference, Southwestern (DNA-protein), and transient-transfection assays and identified the IAP-proximal enhancer (IPE) element that directs differentiation-specific expression. We find that the IPE is inactive in undifferentiated F9 cells and active in differentiated parietal endoderm-like PYS-2 cells. Three proteins of 40, 60, and 68 kDa bind to the sequence GAGTAGAC located between nucleotides -53 and -47 within the IPE. The 40- and 68-kDa proteins from both the undifferentiated and differentiated cells exhibit similar DNA-binding activities. However, the 60-kDa protein from differentiated cells has greater binding activity than that from undifferentiated cells, suggesting a role for this protein in F9 differentiation-specific expression of the IAP gene. The IAP gene is negatively regulated by the adenovirus E1A proteins, and the E1A sequence responsible for repression is located at the N terminus, between amino acids 2 and 67. The DNA sequence that is the target of E1A repression also maps to the IPE element. Colocalization of the differentiation-specific and E1A-sensitive elements to the same protein-binding site within the IPE suggests that the E1A-like activity functions in F9 cells to repress IAP gene expression. Activation of the IAP gene may result when the E1A-like activity is lost or inactivated during F9 cell differentiation, followed by binding of the 60-kDa positive regulatory protein to the enhancer element.
Assuntos
Proteínas E1A de Adenovirus/metabolismo , Diferenciação Celular/genética , DNA Viral/genética , Elementos Facilitadores Genéticos , Regulação Viral da Expressão Gênica , Genes de Partícula A Intracisternal/genética , Sequência de Bases , Dados de Sequência Molecular , Fatores de Transcrição/metabolismo , Transfecção , Células Tumorais CultivadasAssuntos
Doença de Alzheimer/genética , Peptídeos beta-Amiloides/metabolismo , Proteínas de Membrana/genética , Idade de Início , Peptídeos beta-Amiloides/genética , Animais , Humanos , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Mutação , Presenilina-1 , Presenilina-2RESUMO
In Alzheimer's disease (AD), the neuropathologic hallmarks of beta-amyloid deposition and neurofibrillary degeneration are associated with early and progressive pathology of the endosomal-lysosomal system. Abnormalities of autophagy, a major pathway to lysosomes for protein and organelle turnover, include marked accumulations of autophagy-related vesicular compartments (autophagic vacuoles or AVs) in affected neurons. Here, we investigated the possibility that AVs contain the proteases and substrates necessary to cleave the amyloid precursor protein (APP) to A beta peptide that forms beta-amyloid, a key pathogenic factor in AD. AVs were highly purified using a well-established metrizamide gradient procedure from livers of transgenic YAC mice overexpressing wild-type human APP. By Western blot analysis, AVs contained APP, beta CTF - the beta-cleaved carboxyl-terminal domain of APP, and BACE, the protease-mediating beta-cleavage of APP. beta-Secretase activity measured against a fluorogenic peptide was significantly enriched in the AV fraction relative to whole-liver lysate. Compared to other recovered subcellular fractions, AVs exhibited the highest specific activity of gamma-secretase based on a fluorogenic assay and inhibition by a specific inhibitor of gamma-secretase, DAPT. AVs were also the most enriched subcellular fraction in levels of the gamma-secretase components presenilin and nicastrin. Immunoelectron microscopy demonstrated selective immunogold labeling of AVs with antibodies specific for the carboxyl termini of human A beta 40 and A beta 42. These data indicate that AVs are a previously unrecognized and potentially highly active compartment for A beta generation and suggest that the abnormal accumulation of AVs in affected neurons of the AD brain contributes to beta-amyloid deposition.
Assuntos
Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/metabolismo , Autofagia/fisiologia , Endopeptidases/fisiologia , Vacúolos/enzimologia , Secretases da Proteína Precursora do Amiloide , Animais , Ácido Aspártico Endopeptidases , Humanos , Fígado/metabolismo , Fígado/ultraestrutura , Camundongos , Camundongos Transgênicos , Neurônios/metabolismo , Vacúolos/ultraestruturaRESUMO
The endogenous retrovirus, intracisternal A-particle (IAP), is expressed at unique stages during murine embryogenesis and is also activated during the in vitro differentiation of F9 cells. We have examined the DNA elements and protein factors that control IAP expression during F9 differentiation. In the present study an IAP upstream enhancer (IUE) is identified by transient transfection assays and found to be active in both undifferentiated and differentiated cells. Further analyses reveal that a ubiquitous 65 kDa protein factor, the IUE binding protein (IUEB), binds with the IUE. Site-specific methylation within the IUEB binding site strongly inhibits both IUEB binding and IUE transcriptional activity, suggesting that methylation may regulate IUE function and IAP expression.
Assuntos
Fosfatos de Dinucleosídeos/metabolismo , Elementos Facilitadores Genéticos/genética , Genes de Partícula A Intracisternal/genética , Fatores de Transcrição/metabolismo , Transcrição Gênica/genética , Animais , Sequência de Bases , Diferenciação Celular/genética , Deleção Cromossômica , Análise Mutacional de DNA , Proteínas de Ligação a DNA/metabolismo , DNA-Citosina Metilases , Regulação Viral da Expressão Gênica , Células HeLa , Humanos , Metilação , Camundongos , Dados de Sequência Molecular , Sequências Repetitivas de Ácido Nucleico/fisiologia , Retroviridae/genéticaAssuntos
Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/genética , Cromossomos Artificiais de Levedura , Proteínas de Membrana/genética , Precursor de Proteína beta-Amiloide/metabolismo , Animais , Humanos , Camundongos , Camundongos Transgênicos , Mutação , Presenilina-1 , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
Alterations in the processing of the amyloid precursor protein (APP) lead to familial Alzheimer's disease (AD). AD patients exhibit increased seizure susceptibility and alterations in their EEGs, which suggests that APP and its metabolites may modulate neuronal networks. Here we demonstrate that transgenic mice overexpressing APP intracellular domain (AICD) and its binding partner Fe65 exhibit abnormal spiking events and a susceptibility to induced seizures. These abnormalities are not observed in PDAPP(D664A) mice, which express high Aß levels but harbor a mutation in the APP intracellular domain. These data suggest that alterations in the levels of AICD contribute to network dysfunction in AD.
Assuntos
Doença de Alzheimer/genética , Doença de Alzheimer/patologia , Precursor de Proteína beta-Amiloide/biossíntese , Precursor de Proteína beta-Amiloide/genética , Epilepsia/genética , Epilepsia/patologia , Predisposição Genética para Doença/genética , Rede Nervosa/patologia , Doença de Alzheimer/metabolismo , Precursor de Proteína beta-Amiloide/química , Animais , Modelos Animais de Doenças , Epilepsia/metabolismo , Feminino , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Rede Nervosa/fisiologia , Estrutura Terciária de Proteína/genéticaAssuntos
Cromossomos Artificiais de Levedura , Camundongos Transgênicos , Transgenes , Animais , Humanos , CamundongosRESUMO
Mutations in the amyloid precursor protein (APP) gene result in elevated production and deposition of the 42 amino acid beta-amyloid (Abeta1-42) peptide and early-onset Alzheimer's disease (AD). To accurately examine the effect of the APP FAD mutations in vivo, we introduced yeast artificial chromosomes (YACs) containing the entire genomic copy of human APP harboring FAD mutations into transgenic mice. Our current results demonstrate that mutant APP YAC transgenic mice exhibit many features characteristic of human AD, including regional deposition of Abeta with preferential deposition of Abeta1-42, extensive neuritic abnormalities as evidenced by staining with APP, ubiquitin, neurofilament, and hyperphosphorylated tau antibodies, increased markers of inflammation, and the overlapping deposition of Abeta with apolipoproteins E and J. Our results also suggest that APP YAC transgenic mice possess unique pathological attributes when compared to other transgenic mouse models of AD that may reflect the experimental design of each model.
Assuntos
Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/genética , Encéfalo/metabolismo , Encéfalo/patologia , Cromossomos Artificiais de Levedura/genética , Marcação de Genes/métodos , Mutação/genética , Envelhecimento/genética , Envelhecimento/metabolismo , Envelhecimento/patologia , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/genética , Peptídeos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Animais , Apolipoproteínas E/genética , Apolipoproteínas E/metabolismo , Encéfalo/fisiopatologia , Clusterina , Feminino , Glicoproteínas/genética , Glicoproteínas/metabolismo , Humanos , Imuno-Histoquímica , Masculino , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Transgênicos , Chaperonas Moleculares/genética , Chaperonas Moleculares/metabolismo , Neuritos/metabolismo , Neuritos/patologia , Neuroglia/metabolismo , Neuroglia/patologia , Neurônios/metabolismo , Neurônios/patologia , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/metabolismo , Placa Amiloide/genética , Placa Amiloide/metabolismo , Placa Amiloide/patologia , Presenilina-1 , Caracteres SexuaisRESUMO
Using a cloned cDNA to the mouse placental calcium-binding protein (MCaBP) [Tuan and Kirwin, preceding paper], mRNA transcripts of the MCaBP have been localized in the mouse placenta by in situ cDNA-RNA hybridization. The procedure involved the use of a nonradioactive, biotinylated cDNA probe. Paraffin sections of the mouse chorioallantoic placenta were processed for in situ hybridization using a procedure modified from that of Lo [8]. The results demonstrated that MCaBP mRNA is localized specifically to the fetal trophoblast of the mouse placenta, and is expressed in a development-dependent manner. The MCaBP cDNA also hybridized strongly in situ to sections of human term placenta, giving rise to signals localized specifically to the syncytiotrophoblastic layer of the chorionic villi.
Assuntos
Proteínas de Ligação ao Cálcio/metabolismo , Placenta/metabolismo , Proteínas da Gravidez/metabolismo , RNA Mensageiro/análise , Animais , DNA , Humanos , Camundongos , Peso Molecular , Hibridização de Ácido Nucleico , Placenta/citologiaRESUMO
Transgenic mice have been generated from embryonic stem (ES) cells carrying functional genes cloned within yeast artificial chromosomes (YACs). Information on the integrity and organization of the inserted sequences, including the number of copies and their orientation to each other, is still limited by current methods. We have applied fluorescence in situ hybridization to stretched chromatin preparations from YAC-transfected ES cells to analyze the organization and copy number of the integrated sequences.
Assuntos
Cromatina/genética , Cromossomos Artificiais de Levedura , Hibridização in Situ Fluorescente , Transgenes , Animais , Linhagem Celular , Humanos , Células Híbridas , Camundongos , Camundongos Transgênicos , Mapeamento por Restrição , Células-Tronco , Superóxido Dismutase/genética , TransfecçãoRESUMO
Missense mutations in the beta-amyloid precursor protein gene (APP) co-segregate with a small subset of autosomal dominant familial Alzheimer's disease (FAD) cases wherein deposition of the 39-43 amino acid beta-amyloid (A beta) peptide and neurodegeneration are principal neuropathological hallmarks. To accurately examine the effect of missense mutations on APP metabolism and A beta production in vivo, we have introduced yeast artificial chromosomes (YACs) containing the entire approximately 400 kbp human APP gene encoding APP harboring either the asparagine for lysine and leucine for methionine FAD substitution at codons 670 and 671 (APP(K670N/M671L)), the isoleucine for valine FAD substitution at codon 717 (APP(V7171)) or a combination of both substitutions into transgenic mice. We demonstrate that, relative to YAC transgenic mice expressing wild-type APP, high levels of A beta peptides are detected in the brains of YAC transgenic mice expressing human APP(K670N/M671L) that is associated with a concomitant diminution in the levels of apha-secretase-generated soluble APP derivatives. Moreover, the levels of longer A beta peptides (species terminating at amino acids 42/43) are elevated in YAC transgenic mice expressing human APP(V7171). These mice should prove valuable for detailed analysis of the in vivo effects of the APP FAD mutations in a variety of tissues and throughout aging and for testing therapeutic agents that specifically alter APP metabolism and A beta production.
Assuntos
Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/metabolismo , Cromossomos Artificiais de Levedura , Precursor de Proteína beta-Amiloide/genética , Animais , Técnicas de Cultura de Células , Expressão Gênica , Vetores Genéticos , Humanos , Camundongos , Camundongos Transgênicos/genética , Mutagênese , Reação em Cadeia da Polimerase , RNA Mensageiro/metabolismo , Transgenes/genéticaRESUMO
Experimental thiamine deficiency (TD) is a classical model of a nutritional deficit associated with a generalized impairment of oxidative metabolism and selective cell loss in the brain. In rats, TD-induced cell degeneration is accompanied by an accumulation of amyloid precursor protein (APP)/amyloid precursor-like protein 2 (APLP2) immunoreactivity in abnormal neurites and perikarya along the periphery of, or scattered within, the lesion. Prompted by these data and our previous findings of a genetic variation in the development of TD symptoms, we extended our studies to mice. C57BL/6, ApoE knockout, and APP YAC transgenic mice received thiamine-deficient diet and pyrithiamine injections. Unlike rats, APP/APLP2-immunoreactive neurites in all strains of mice were sparsely scattered within damaged areas and did not delimit the thalamic lesion. In addition, abnormal clusters of intensely immunoreactive neurites occurred only in areas of damage including the thalamus, mammillary body, and inferior colliculus. The clusters appeared as either irregular clumps or round or oval rosettes that strikingly resembled the neuritic component of Alzheimer amyloid plaques. However, immunostaining using various antisera to synthetic amyloid beta-protein (A beta 1-40) and thioflavine S histochemistry failed to show evidence of a component of A beta Neither APP/APLP2-immunoreactive clusters nor amyloid plaques were observed in the brain from patients with Wernicke-Korsakoff syndrome, the clinical manifestation of TD in man. Our results demonstrate species (i.e., genetic) differences in the response to TD-induced damage and support a role for APP and APLP2 in the response to brain injury. This is the first report that chronic oxidative deficits can lead to this novel pathology.